April 01, 2026 10:32 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Bengal SIR progress: 47 lakh of 60 lakh adjudicated cases disposed of, Supreme Court informed | Amit Shah to join Suvendu Adhikari on Bhabanipur nomination day; BJP plans mega roadshow | Fuel prices rise: Premium petrol, diesel hiked amid oil price surge | Commercial LPG up Rs 195.50 as global oil prices rise; domestic rates unchanged | Layoff alert: Oracle cuts 30,000 jobs globally, 12,000 hit in India | ‘Unsubstantial allegations’: Calcutta HC dismisses plea on ECI’s officer transfers in Bengal | Tennis icon Leander Paes joins BJP ahead of Bengal polls | 8 killed, several injured in crowd crush at Bihar temple in Nalanda | Trump signals exit from Iran war even as Strait of Hormuz remains shut: Report | Mystery death in Pakistan: JeM chief Masood Azhar’s brother found dead
Covid-19 vaccines

Two Covid-19 vaccine candidates await DCGI approval for emergency use in India

| @indiablooms | Jan 03, 2021, at 04:24 pm

New Delhi/IBNS: Two Covid-19 vaccine candidates in India-Hyderabad-based Bharat Biotech's Covaxin and the Serum Institute of India's Covishield-now awaits the approval of the Drugs Controller General of India (DCGI) for emergency use after they have been cleared by the government-appointed panel.

DCGI chief Dr Venugopal G Somani is expected to share details about the vaccine candidates on Sunday.

The government-appointed panel of experts on Saturday cleared the emergency use of indigenous COVID-19 vaccine Covaxin manufactured by Hyderabad-based Bharat Biotech and recommended for approval to the regulator Drugs Controller General of India (DCGI).

The recommendation for the home-grown vaccine came a day after the expert panel cleared Covishield developed by Oxford University and pharma major AstraZeneca to be manufactured by Serum Institute of India (SII).

The Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) recommended the Drugs Controller General of India (DCGI) to grant permission to Bharat Biotech's Covaxin.

According to reports, the SEC met on Jan 1 and 2 and made the recommendations for the consideration and final decision of DGCI, said the Union Health Ministry.

The Serum Institute of India (SII) is making the vaccine Covishield developed by Oxford University and pharma major AstraZeneca, while Bharat Biotech has partnered with the Indian Council of Medical Research (ICMR) for its indigenous Covaxin.

The final decision to recommend Bharat Biotech's Covaxin came after it presented updated data and justification and request for consideration of their proposal amid cases of mutant Coronavirus strain.

The committee noted that the vaccine has the potential to target mutated coronavirus strains, media reports said.
 

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.